Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $12,000.

  • Lineage Cell Therapeutics' Capital Expenditures fell 89.29% to $12,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $488,000, marking a year-over-year increase of 67.70%. This contributed to the annual value of $565,000 for FY2024, which is 16.17% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Capital Expenditures stood at $12,000, which was down 14.29% from $14,000 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Capital Expenditures registered a high of $365,000 during Q4 2024, and its lowest value of -$16,000 during Q4 2022.
  • In the last 3 years, Lineage Cell Therapeutics' Capital Expenditures had a median value of $97,000 in 2025 and averaged $123,818.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Capital Expenditures soared by 2,050.00% in 2021 and then tumbled by 110.96% in 2022.
  • Lineage Cell Therapeutics' Capital Expenditures (Quarterly) stood at $146,000 in 2021, then plummeted by 110.96% to -$16,000 in 2022, then skyrocketed by 668.75% to $91,000 in 2023, then spiked by 301.10% to $365,000 in 2024, then plummeted by 89.29% to $12,000 in 2025.
  • Its Capital Expenditures was $12,000 in Q3 2025, compared to $14,000 in Q2 2025 and $97,000 in Q1 2025.